|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHMP5 |
Gene summary for CHMP5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHMP5 | Gene ID | 51510 |
| Gene name | charged multivesicular body protein 5 | |
| Gene Alias | C9orf83 | |
| Cytomap | 9p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q9NZZ3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51510 | CHMP5 | P4T-E | Human | Esophagus | ESCC | 1.99e-43 | 1.01e+00 | 0.1323 |
| 51510 | CHMP5 | P5T-E | Human | Esophagus | ESCC | 2.76e-91 | 2.01e+00 | 0.1327 |
| 51510 | CHMP5 | P8T-E | Human | Esophagus | ESCC | 4.37e-46 | 9.91e-01 | 0.0889 |
| 51510 | CHMP5 | P9T-E | Human | Esophagus | ESCC | 2.13e-43 | 1.33e+00 | 0.1131 |
| 51510 | CHMP5 | P10T-E | Human | Esophagus | ESCC | 4.70e-56 | 9.78e-01 | 0.116 |
| 51510 | CHMP5 | P11T-E | Human | Esophagus | ESCC | 1.83e-35 | 1.40e+00 | 0.1426 |
| 51510 | CHMP5 | P12T-E | Human | Esophagus | ESCC | 1.73e-66 | 1.40e+00 | 0.1122 |
| 51510 | CHMP5 | P15T-E | Human | Esophagus | ESCC | 1.42e-42 | 9.81e-01 | 0.1149 |
| 51510 | CHMP5 | P16T-E | Human | Esophagus | ESCC | 1.26e-35 | 4.84e-01 | 0.1153 |
| 51510 | CHMP5 | P17T-E | Human | Esophagus | ESCC | 5.85e-21 | 1.09e+00 | 0.1278 |
| 51510 | CHMP5 | P19T-E | Human | Esophagus | ESCC | 5.30e-15 | 1.37e+00 | 0.1662 |
| 51510 | CHMP5 | P20T-E | Human | Esophagus | ESCC | 1.52e-32 | 8.27e-01 | 0.1124 |
| 51510 | CHMP5 | P21T-E | Human | Esophagus | ESCC | 2.13e-71 | 1.43e+00 | 0.1617 |
| 51510 | CHMP5 | P22T-E | Human | Esophagus | ESCC | 1.30e-39 | 7.73e-01 | 0.1236 |
| 51510 | CHMP5 | P23T-E | Human | Esophagus | ESCC | 1.52e-39 | 9.86e-01 | 0.108 |
| 51510 | CHMP5 | P24T-E | Human | Esophagus | ESCC | 3.67e-52 | 1.15e+00 | 0.1287 |
| 51510 | CHMP5 | P26T-E | Human | Esophagus | ESCC | 7.32e-78 | 1.22e+00 | 0.1276 |
| 51510 | CHMP5 | P27T-E | Human | Esophagus | ESCC | 5.58e-27 | 5.83e-01 | 0.1055 |
| 51510 | CHMP5 | P28T-E | Human | Esophagus | ESCC | 8.46e-99 | 2.19e+00 | 0.1149 |
| 51510 | CHMP5 | P30T-E | Human | Esophagus | ESCC | 1.20e-58 | 2.58e+00 | 0.137 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
| GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
| GO:0016197 | Colorectum | AD | endosomal transport | 90/3918 | 230/18723 | 1.88e-10 | 1.73e-08 | 90 |
| GO:0022411 | Colorectum | AD | cellular component disassembly | 147/3918 | 443/18723 | 8.53e-10 | 6.76e-08 | 147 |
| GO:0051656 | Colorectum | AD | establishment of organelle localization | 131/3918 | 390/18723 | 3.00e-09 | 2.06e-07 | 131 |
| GO:0006900 | Colorectum | AD | vesicle budding from membrane | 32/3918 | 61/18723 | 5.38e-08 | 2.81e-06 | 32 |
| GO:0032984 | Colorectum | AD | protein-containing complex disassembly | 81/3918 | 224/18723 | 9.41e-08 | 4.65e-06 | 81 |
| GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
| GO:0007034 | Colorectum | AD | vacuolar transport | 60/3918 | 157/18723 | 4.97e-07 | 1.85e-05 | 60 |
| GO:0043112 | Colorectum | AD | receptor metabolic process | 62/3918 | 166/18723 | 8.18e-07 | 2.85e-05 | 62 |
| GO:1901653 | Colorectum | AD | cellular response to peptide | 114/3918 | 359/18723 | 8.32e-07 | 2.88e-05 | 114 |
| GO:0001881 | Colorectum | AD | receptor recycling | 18/3918 | 33/18723 | 2.23e-05 | 4.40e-04 | 18 |
| GO:0036257 | Colorectum | AD | multivesicular body organization | 17/3918 | 31/18723 | 3.45e-05 | 6.29e-04 | 17 |
| GO:0000910 | Colorectum | AD | cytokinesis | 59/3918 | 173/18723 | 3.74e-05 | 6.75e-04 | 59 |
| GO:0071985 | Colorectum | AD | multivesicular body sorting pathway | 19/3918 | 37/18723 | 4.08e-05 | 7.26e-04 | 19 |
| GO:0007032 | Colorectum | AD | endosome organization | 33/3918 | 82/18723 | 5.30e-05 | 9.01e-04 | 33 |
| GO:0007041 | Colorectum | AD | lysosomal transport | 42/3918 | 114/18723 | 6.61e-05 | 1.07e-03 | 42 |
| GO:0036258 | Colorectum | AD | multivesicular body assembly | 16/3918 | 30/18723 | 9.18e-05 | 1.40e-03 | 16 |
| GO:0032509 | Colorectum | AD | endosome transport via multivesicular body sorting pathway | 16/3918 | 31/18723 | 1.53e-04 | 2.16e-03 | 16 |
| GO:0061640 | Colorectum | AD | cytoskeleton-dependent cytokinesis | 37/3918 | 100/18723 | 1.58e-04 | 2.20e-03 | 37 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041442 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
| hsa04217 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| hsa041443 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
| hsa042171 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa0414420 | Endometrium | AEH | Endocytosis | 56/1197 | 251/8465 | 2.58e-04 | 2.15e-03 | 1.57e-03 | 56 |
| hsa04144110 | Endometrium | AEH | Endocytosis | 56/1197 | 251/8465 | 2.58e-04 | 2.15e-03 | 1.57e-03 | 56 |
| hsa0414424 | Endometrium | EEC | Endocytosis | 57/1237 | 251/8465 | 3.34e-04 | 2.82e-03 | 2.10e-03 | 57 |
| hsa0414434 | Endometrium | EEC | Endocytosis | 57/1237 | 251/8465 | 3.34e-04 | 2.82e-03 | 2.10e-03 | 57 |
| hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHMP5 | SNV | Missense_Mutation | c.107N>G | p.Ser36Cys | p.S36C | Q9NZZ3 | protein_coding | deleterious(0.02) | possibly_damaging(0.676) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| CHMP5 | SNV | Missense_Mutation | c.80G>C | p.Arg27Thr | p.R27T | Q9NZZ3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| CHMP5 | SNV | Missense_Mutation | novel | c.261C>A | p.Phe87Leu | p.F87L | Q9NZZ3 | protein_coding | deleterious(0) | benign(0.35) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| CHMP5 | SNV | Missense_Mutation | rs758726437 | c.376N>A | p.Asp126Asn | p.D126N | Q9NZZ3 | protein_coding | tolerated(0.13) | benign(0.08) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CHMP5 | SNV | Missense_Mutation | c.138N>T | p.Lys46Asn | p.K46N | Q9NZZ3 | protein_coding | deleterious(0) | possibly_damaging(0.547) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CHMP5 | SNV | Missense_Mutation | rs758726437 | c.376N>A | p.Asp126Asn | p.D126N | Q9NZZ3 | protein_coding | tolerated(0.13) | benign(0.08) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CHMP5 | SNV | Missense_Mutation | c.551N>G | p.Asp184Gly | p.D184G | Q9NZZ3 | protein_coding | tolerated(0.12) | benign(0.137) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CHMP5 | SNV | Missense_Mutation | novel | c.433N>G | p.Ile145Val | p.I145V | Q9NZZ3 | protein_coding | tolerated(0.39) | benign(0.019) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| CHMP5 | SNV | Missense_Mutation | novel | c.343N>A | p.Glu115Lys | p.E115K | Q9NZZ3 | protein_coding | deleterious(0.01) | benign(0.41) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| CHMP5 | SNV | Missense_Mutation | c.337N>T | p.Val113Leu | p.V113L | Q9NZZ3 | protein_coding | tolerated(0.4) | benign(0.001) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |